Bausch targets Sandoz over IBS generic

03-10-2019

Rory O'Neill

Bausch targets Sandoz over IBS generic

Pavel Kapysh / Shutterstock.com

Canadian pharmaceutical company Bausch Health is suing Sandoz for patent infringement over its notice of intent to release a generic version of Xifaxan (rifaximin), Bausch’s irritable bowel syndrome (IBS) drug.


Bausch Health, Xifaxan, IBS, irritable bowel syndrome, rifaximin, Actavis, Teva, Sandoz, Novartis, Salix Pharmaceuticals, Alfasigma

More on this story

Bausch Health resolves IBS patent litigation
07-05-2020

LSIPR